goodcap

Goodcap is a global leader in psychedelics that focuses on psilocybin and other natural compounds to promote emotional, mental, and physical health. Goodcap's mission is to develop a safer and more effective therapy to help patients with inflammation, initially focusing on depression. Goodcap’s leading project, GCAP001, is a novel combination drug product designed to significantly enhance the benefits of non-toxic doses of psilocybin. It is a multi-receptor agonist targeting gastrointestinal inflammation and brain chemistry, influencing depression, and has the potential to expand into other inflammation-based indications.